Weibin Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Weibin Hu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Fengyun Zhao
Cancer Research Institute of Zhongshan City Zhongshan City People's Hospital Zhongshan 528403 China
2 shared publications - Jingmin Li
Key Laboratory of Brain Cognition and Education Sciences Ministry of Education China Institute for Brain Research and Rehabilitation South China Normal University Guangzhou 510631 China
2 shared publications - Li-Sheng Wang
Department of Gastroenterology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, 518020, People’s Republic of China
2 shared publications Shaohui Tang
Department of Gastroenterology The First Affiliated Hospital of Jinan University Guangzhou 510630 China
2 shared publications- Xiaodong Ma
Key Laboratory of Brain, Cognition and Education Sciences, Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of Mental Health and Cognitive Science, Ministry of Education, South China Normal University, Guangzhou 510631, China
2 shared publications - Zhi Cao
Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou 510631, China
2 shared publications
Latest Publications
- 18 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (11) , e2404935
Near‐Infrared Imaging Agent ABSi‐148 Alleviates CA IX‐Mediated Hypoxic Fibrosis in Inflammation‐Cancer Transition
Pancreatic ductal adenocarcinoma (PDAC) remains a formidable challenge due to its late diagnosis and intrinsic treatment resistance, exacerbates by its development from chronic inflammation to cancer transition (ICT). Here, this investigation aims to develop and evaluate ABSi‐148, a novel near‐infrared (NIR) agent targeting hypoxic carbonic anhydrase IX (CA IX), for its potential applications in ICT imaging and even PDAC treatment. ABSi‐148 is synthesized from 4‐(2‐Aminoethyl) benzene sulfonamide (ABS), a sulfonamide derivative, conjugating with MHI‐148 dye with merits of exceptional NIR‐emitting traits, high biocompatibility, and deep tissue penetration imaging capability. It selectively accumulates in CoCl2‐induced pancreatic stellate cells and pancreatic cancer cells via binding with transmembrane CA IX in vitro. Meanwhile, ABSi‐148 effectively visualizes the early pancreatic lesion, and its long‐term administration inhibits the progression of hypoxia‐related fibrosis involved in pancreatic intraepithelial neoplasias (PanINs), and even PDAC progression in vivo. Besides, ABSi‐148 monitors treatment efficacy and localizes hypoxic tumor regions, enhancing survival in tamoxifen combined with caerulein‐induced KPC mice. Overall, ABSi‐148 emerges as a theranostic NIR agent for precise diagnosis and targeted therapy in ICT of PDAC, promising to alleviate tumor progression and enhancing outcomes.
- 18 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (11) , e2404935
Near‐Infrared Imaging Agent ABSi‐148 Alleviates CA IX‐Mediated Hypoxic Fibrosis in Inflammation‐Cancer Transition
Pancreatic ductal adenocarcinoma (PDAC) remains a formidable challenge due to its late diagnosis and intrinsic treatment resistance, exacerbates by its development from chronic inflammation to cancer transition (ICT). Here, this investigation aims to develop and evaluate ABSi‐148, a novel near‐infrared (NIR) agent targeting hypoxic carbonic anhydrase IX (CA IX), for its potential applications in ICT imaging and even PDAC treatment. ABSi‐148 is synthesized from 4‐(2‐Aminoethyl) benzene sulfonamide (ABS), a sulfonamide derivative, conjugating with MHI‐148 dye with merits of exceptional NIR‐emitting traits, high biocompatibility, and deep tissue penetration imaging capability. It selectively accumulates in CoCl2‐induced pancreatic stellate cells and pancreatic cancer cells via binding with transmembrane CA IX in vitro. Meanwhile, ABSi‐148 effectively visualizes the early pancreatic lesion, and its long‐term administration inhibits the progression of hypoxia‐related fibrosis involved in pancreatic intraepithelial neoplasias (PanINs), and even PDAC progression in vivo. Besides, ABSi‐148 monitors treatment efficacy and localizes hypoxic tumor regions, enhancing survival in tamoxifen combined with caerulein‐induced KPC mice. Overall, ABSi‐148 emerges as a theranostic NIR agent for precise diagnosis and targeted therapy in ICT of PDAC, promising to alleviate tumor progression and enhancing outcomes.
- 27 September 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (32) , e2402913
Letrozole‐Based Near‐Infrared Dynamic Imaging Targeting Ductal‐Vascular RhoJ From Pancreatic Intraepithelial Neoplasia to Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) relies heavily on neoangiogenesis for its progression, making early detection crucial. Here, LTZi‐MHI148 (Letrozole inhibitor bonding with MHI‐148 dye), a near‐infrared (NIR) fluorescent agent is developed, to target RhoJ (Ras Homolog Family Member J), a protein expressed in neonatal vasculature, for both imaging and therapy of early PDAC. This agent is synthesized by conjugating Letrozole with MHI‐148, exhibiting excellent NIR characteristics and photostability. In vitro studies showed that LTZi‐MHI148 selectively accumulated within pancreatic cancer cells through Organic Anion Transporting Polypeptide (OATP) transporters and bound to cytoplasmic RhoJ. In vivo, the probe effectively targeted neoangiogenesis and Pancreatic Intraepithelial Neoplasias (PanINs) in various PDAC models, including the orthotopic, ectopic, spontaneous, and tamoxifen‐induced tumors. Notably, LTZi‐MHI148 detected preneoplastic PanIN lesions with Overexpressed RhoJ and active neoangiogenesis in both spontaneous and tamoxifen‐induced PDAC murine models. Longitudinal imaging studies revealed that RhoJ‐targeted neoangiogenesis tracks lesion progression, highlighting LTZi‐MHI148's utility in monitoring disease progression. Furthermore, multiple LTZi‐MHI148 administrations attenuated PanINs to PDAC progression, suggesting its potential as a therapeutic intervention. These findings underscore the translational potential of LTZi‐MHI148 for the early detection and targeted therapy of PDAC, utilizing NIR‐I/II imaging to monitor RhoJ overexpression in precancerous ductal neoplasia associated with neoangiogenesis.
- 27 September 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (32) , e2402913
Letrozole‐Based Near‐Infrared Dynamic Imaging Targeting Ductal‐Vascular RhoJ From Pancreatic Intraepithelial Neoplasia to Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) relies heavily on neoangiogenesis for its progression, making early detection crucial. Here, LTZi‐MHI148 (Letrozole inhibitor bonding with MHI‐148 dye), a near‐infrared (NIR) fluorescent agent is developed, to target RhoJ (Ras Homolog Family Member J), a protein expressed in neonatal vasculature, for both imaging and therapy of early PDAC. This agent is synthesized by conjugating Letrozole with MHI‐148, exhibiting excellent NIR characteristics and photostability. In vitro studies showed that LTZi‐MHI148 selectively accumulated within pancreatic cancer cells through Organic Anion Transporting Polypeptide (OATP) transporters and bound to cytoplasmic RhoJ. In vivo, the probe effectively targeted neoangiogenesis and Pancreatic Intraepithelial Neoplasias (PanINs) in various PDAC models, including the orthotopic, ectopic, spontaneous, and tamoxifen‐induced tumors. Notably, LTZi‐MHI148 detected preneoplastic PanIN lesions with Overexpressed RhoJ and active neoangiogenesis in both spontaneous and tamoxifen‐induced PDAC murine models. Longitudinal imaging studies revealed that RhoJ‐targeted neoangiogenesis tracks lesion progression, highlighting LTZi‐MHI148's utility in monitoring disease progression. Furthermore, multiple LTZi‐MHI148 administrations attenuated PanINs to PDAC progression, suggesting its potential as a therapeutic intervention. These findings underscore the translational potential of LTZi‐MHI148 for the early detection and targeted therapy of PDAC, utilizing NIR‐I/II imaging to monitor RhoJ overexpression in precancerous ductal neoplasia associated with neoangiogenesis.
- Open Access
- 27 October 2021
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 30 (12) , 1271-1281
Identification and functional analysis of changes to the ox-LDL-induced microRNA-124-3p/DLX5 axis in vascular smooth muscle cells
The microRNA (miR)-mRNA axes involved in oxidized low-density lipoprotein (ox-LDL)-induced vascular smooth muscle cells (VSMCs) proliferation/apoptosis imbalance need to be investigated in more detail. To investigate the function and any relevant changes to miR-mRNA axes in the ox-LDL-induced proliferation/apoptosis imbalance in VSMCs. Human VSMCs were cultured and treated with ox-LDL in vitro. The differentially expressed (DE) miRs and mRNAs in VSMCs following 48-h ox-LDL treatment were detected using RNA sequencing. Candidate miRs and mRNAs were further selected, based on comprehensive bioinformatics analysis. Changes in the expression of candidate miRs and mRNAs in ox-LDL-treated VSMCs were confirmed with quantitative real-time polymerase chain reaction (RT-qPCR) and western blot. The inhibitory effect of candidate miRs on mRNAs were demonstrated using a dual luciferase reporter assay. The functional role of candidate miRs and mRNAs on proliferation, cell cycle and apoptosis of VSMCs were estimated using cell couting kit-8 (CCK-8) and flow cytometry assays, respectively. The RNA sequencing data indicated that 577 mRNAs and 81 miRs were significantly upregulated in VSMCs following ox-LDL treatment. Gene function and pathway enrichment analysis suggested that the DE-mRNAs and miRs participate in the regulation of proliferation, cell cycle and apoptosis. Increased expression of DLX5 with decreasing miR-124-3p levels were confirmed in ox-LDL-treated VSMCs. The miR-124-3p could inhibit the DLX5 level by binding the 3' UTR of DLX5 mRNA. Functional analysis showed that the alteration of miR-124-3p/DLX5 expression mediated the effect of ox-LDL on VSMCs proliferation/apoptosis imbalance. The ox-LDL affects the VSMC proliferation/apoptosis balance via the miR-124-3p/DLX5 axis, which results in VSMC hyperproliferation. The miR-124-3p/DLX5 axis might serve as a therapeutic molecular target to reverse the effect of ox-LDL and prevent atherosclerosis (AS) development and progression.
- 27 October 2021
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 30 (12) , 1271-1281
Open AccessIdentification and functional analysis of changes to the ox-LDL-induced microRNA-124-3p/DLX5 axis in vascular smooth muscle cells
The microRNA (miR)-mRNA axes involved in oxidized low-density lipoprotein (ox-LDL)-induced vascular smooth muscle cells (VSMCs) proliferation/apoptosis imbalance need to be investigated in more detail. To investigate the function and any relevant changes to miR-mRNA axes in the ox-LDL-induced proliferation/apoptosis imbalance in VSMCs. Human VSMCs were cultured and treated with ox-LDL in vitro. The differentially expressed (DE) miRs and mRNAs in VSMCs following 48-h ox-LDL treatment were detected using RNA sequencing. Candidate miRs and mRNAs were further selected, based on comprehensive bioinformatics analysis. Changes in the expression of candidate miRs and mRNAs in ox-LDL-treated VSMCs were confirmed with quantitative real-time polymerase chain reaction (RT-qPCR) and western blot. The inhibitory effect of candidate miRs on mRNAs were demonstrated using a dual luciferase reporter assay. The functional role of candidate miRs and mRNAs on proliferation, cell cycle and apoptosis of VSMCs were estimated using cell couting kit-8 (CCK-8) and flow cytometry assays, respectively. The RNA sequencing data indicated that 577 mRNAs and 81 miRs were significantly upregulated in VSMCs following ox-LDL treatment. Gene function and pathway enrichment analysis suggested that the DE-mRNAs and miRs participate in the regulation of proliferation, cell cycle and apoptosis. Increased expression of DLX5 with decreasing miR-124-3p levels were confirmed in ox-LDL-treated VSMCs. The miR-124-3p could inhibit the DLX5 level by binding the 3' UTR of DLX5 mRNA. Functional analysis showed that the alteration of miR-124-3p/DLX5 expression mediated the effect of ox-LDL on VSMCs proliferation/apoptosis imbalance. The ox-LDL affects the VSMC proliferation/apoptosis balance via the miR-124-3p/DLX5 axis, which results in VSMC hyperproliferation. The miR-124-3p/DLX5 axis might serve as a therapeutic molecular target to reverse the effect of ox-LDL and prevent atherosclerosis (AS) development and progression.